Curative effect and safety of olmesartan on chronic heart failure
GUO Lin-lin
CAO Guang-zhi
WANG Tao
ZHAO Liang-ge
BU Xiao-cui
Abstract：Objective To discuss the curative effect and safety of olmesartan on chronic heart failure (CHF). Methods The CHF patients (n=120, male 50 and female 70) were chosen from the Cardiovascular Hospital affiliated to Qingdao University Medical College from Nov. 2011 to Oct. 2013. All patients were divided into groupⅠand groupⅡ(each n=60) according to random digits table. All groups were treated with routine therapy (individualized administrations of cardiotonics, diuretics, aldosterone receptor antagonist andβ-receptor blockers), and group Ⅰ was additionally given olmesartan, and group Ⅱ, valsartan for 8 w. The changes of LVEDd and LVEF, level of N-terminal pro brain natriuretic peptide (NT-proBNP), blood pressure (BP) and renal function were detected in 2 groups before and 8 w after treatment. Results After treatment, LVEDd decreased in groupⅠ[(58.5 ±6.4) mm vs. (52.2±6.0) mm] and groupⅡ(58.2±5.9) mm vs. (52.8±5.8) mm], and LVEF increased in groupⅠ[(39.2±5.2)%vs. (52.1±3.8)%] and groupⅡ[(39.8±6.0)%vs. (50.6±2.7)%, all P<0.05]. After treatment, NT-proBNP decreased significantly in groupⅠ[(934.0±217.7) pg/ml vs. (184.7±66.6) pg/ml] and groupⅡ[(935.0 ±224.6) pg/ml vs. (191.6±70.2) pg/ml, all P<0.05]. After treatment, BP decreased significantly in groupⅠand groupⅡ(all P<0.01). Conclusion Olmesartan can improve heart function and reduce level of NT-proBNP in CHF patients, and its curative effect is not worse than that of valsartan.
Keywords：Olmesartanvalsartancongestive heart failureN-terminal pro brain natriuretic peptide
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 571-573 )